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Abstract
Background
Emerging studies have investigated the association between puberty timing, particularly
age at menarche (AAM), and type 2 diabetes. However, whether this association is indepen-
dent of adiposity is unclear. We aimed to systematically review published evidence on the
association between puberty timing and type 2 diabetes (T2D) or impaired glucose toler-
ance (IGT), with and without adjustment for adiposity, and to estimate the potential contribu-
tion of puberty timing to the burden of T2D in the United Kingdom (UK).
Methods and findings
We searched PubMed, Medline, and Embase databases for publications until February
2019 on the timing of any secondary sexual characteristic in boys or girls in relation to T2D/
IGT. Inverse-variance-weighted random-effects meta-analysis was used to pool reported
estimates, and meta-regression was used to explore sources of heterogeneity. Twenty-
eight observational studies were identified. All assessed AAM in women (combined N =
1,228,306); only 1 study additionally included men. In models without adjustment for adult
adiposity, T2D/IGT risk was lower per year later AAM (relative risk [RR] = 0.91, 95% CI
0.89–0.93, p < 0.001, 11 estimates, n = 833,529, I2 = 85.4%) and higher for early versus
later menarche (RR = 1.39, 95% CI 1.25–1.55, p < 0.001, 23 estimates, n = 1,185,444, I2 =
87.8%). Associations were weaker but still evident in models adjusted for adiposity (AAM:
RR = 0.97 per year, 95% CI 0.95–0.98, p < 0.001, 12 estimates, n = 852,268, I2 = 51.8%;
early menarche: RR = 1.19, 95% CI 1.11–1.28, p < 0.001, 21 estimates, n = 890,583, I2 =
68.1%). Associations were stronger among white than Asian women, and in populations
with earlier average AAM. The estimated population attributable risk of T2D in white UK
women due to early menarche unadjusted and adjusted for adiposity was 12.6% (95% CI
11.0–14.3) and 5.1% (95% CI 3.6–6.7), respectively. Findings in this study are limited by
residual and unmeasured confounding, and self-reported AAM.
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Conclusions
Earlier AAM is consistently associated with higher T2D/IGT risk, independent of adiposity.
More importantly, this research has identified that a substantial proportion of T2D in women
is related to early menarche, which would be expected to increase in light of global secular
trends towards earlier puberty timing. These findings highlight the need to identify the under-
lying mechanisms linking early menarche to T2D/IGT risk.
Author summary
Why was this study done?
• Secular trends towards earlier puberty timing have led to interest in its long-term dis-
ease consequences, particularly the association between early age at menarche in
women and the development of type 2 diabetes.
• An earlier pooled analysis of the association between puberty timing and risk of type 2
diabetes was limited to findings adjusted for adulthood adiposity and included studies
mainly among Western women.
• The present study aimed to evaluate whether puberty timing is associated with type 2
diabetes/impaired glucose tolerance, independent of adiposity.
What did the researchers do and find?
• This systematic review identified 28 observational studies that analysed age at menarche
among women and type 2 diabetes/impaired glucose tolerance; 1 study additionally
included age at voice breaking in men.
• Meta-analysis showed that risk for type 2 diabetes and impaired glucose tolerance is
higher among women with early than later menarche, independent of adiposity.
• The risk for type 2 diabetes and impaired glucose tolerance among women with early
menarche is even higher in white than Asian women and in populations with younger
average age at menarche.
What do these findings mean?
• Girls who experience earlier menarche than their peers within and between populations
have a higher risk for type 2 diabetes in adulthood.
• Preventive strategies that avoid early puberty timing might reduce future risk of type 2
diabetes.
Meta-analysis of puberty timing and diabetes
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Abbreviations: AAM, age at menarche; BMI, body
mass index; HR, hazard ratio; IGT, impaired
glucose tolerance; OR, odds ratio; RR, relative risk;
T2D, type 2 diabetes.
Introduction
Puberty is the transitional period from childhood to adulthood when physiological and physi-
cal changes relating to sexual maturation occur to attain fertility. The onset of puberty is indi-
cated by the appearance of breast buds in girls, genital development in boys, and pubic hair
growth in both sexes, as defined and assessed by the Tanner scale [1,2]. In the later period of
puberty (at Tanner stage 3 or 4), girls experience first menstruation, namely menarche [3], and
boys experience voice break [4]. Within populations, timing of puberty varies widely by sex
and between individuals. Recently reported age at onset of puberty ranges from 8 to 13 years
in girls and from 9 to 14 years in boys [5,6]. However, marked decreases in the age of puberty
are reported worldwide, particularly for age at menarche (AAM) in women, which tends to be
widely assessed in studies [5,7–9], and it has been postulated that these trends reflect decreases
in childhood undernutrition and increases in childhood adiposity [3].
In light of these secular trends, puberty timing has been widely examined in relation to
health outcomes, including type 2 diabetes (T2D), which is increasingly prevalent worldwide
[10]. An earlier systematic review and meta-analysis showed that early menarche was associ-
ated with higher T2D risk [11]. That review identified 10 relevant publications (315,428 partic-
ipants) dated until the end of 2013 and included only 2 studies in non-Western settings (both
were from China) [11], which did not allow for comparisons between regions. There have
been several very large Asian studies published subsequently [12,13]. More importantly, this
previous meta-analysis analysed only effect estimates adjusted for body mass index (BMI) [11].
As BMI was invariably measured in adulthood, rather than in childhood, it may be considered
as a mediator between puberty timing and T2D, rather than simply a confounder, although
BMI, overweight, and obesity track from early childhood to adulthood [14,15]. Comparison of
the associations between puberty timing and T2D with and without adjustment for adiposity
would be informative. Furthermore, a recent study from China reported that the association
between AAM and incident diabetes differed by year of birth, with a stronger association
observed in women who were born in more recent decades [12]. Such potential effect modifi-
cations were not investigated in the previous meta-analysis [11].
Here, we describe a systematic review and meta-analysis to evaluate the association between
puberty timing and T2D and/or impaired glucose tolerance (IGT), with and without adjust-
ment for adiposity, in both women and men. We also assess study-design-related factors that
could explain the heterogeneity between study estimates. Finally, we estimate the potential
contribution of early menarche to the population burden of T2D.
Methods
Study inclusion criteria
Published papers were included in the present systematic review if they reported (i) any mea-
sure of puberty timing reported in childhood or adulthood (pubertal onset: age at breast or
genital development or Tanner stage 2 pubic hair [1,2]; pubertal completion: AAM or age at
voice breaking) and (ii) T2D/IGT assessed by fasting plasma glucose, oral glucose tolerance
test, and/or glycated haemoglobin; self-reported by participants; or based on medical records/
physician diagnosis. No restriction was given to the sex or geographical locations of studied
populations, nor to the type of study design, whether observational or experimental.
Exclusion criteria
We excluded studies that analysed populations with specific diseases such as breast cancer,
polycystic ovary syndrome, Turner syndrome, premature adrenarche, and type 1 or 2 diabetes,
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as well as animal studies. Papers published without a full report available in English language
were not excluded by our search terms; however, no such paper was considered potentially rel-
evant on screening of titles and abstracts in English.
Data sources and searches
We searched online databases (i.e., PubMed, Medline, and Embase) until 28 February 2019.
The search terms were (i) terms or measures related to puberty timing (e.g., puberty, menar-
che, voice break, Tanner) and (ii) terms or measures related to diabetes (e.g., diabetes, glucose,
insulin, glycated haemoglobin) and (iii) terms related to epidemiological studies (based on
guidelines from the Scottish Intercollegiate Guidelines Network) [16]. Further details of the
search strategy are shown in S1 Table. All identified papers were screened by title and abstract,
and if considered potentially relevant, the full texts were read for inclusion decision. Any
uncertainty about the eligibility of a particular study was resolved through discussion between
authors (TSC and KKO). We also reviewed studies included in the previous systematic review
[11] and the reference lists of our included papers to identify relevant papers. The present
study was registered in the International Prospective Register of Systematic Reviews (PROS-
PERO registration number: CRD42019124353), and the protocol is available at: http://www.
crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42019124353.
Data extraction
Data from eligible studies for systematic review were extracted by one author (TSC); a 20%
sample was independently extracted by a second author (RL), blinded to the original dataset,
which was verified (100% agreement) by a third author (KKO).
Extracted information included first author, publication year, sample size, study population
and ethnicity, year at enrolment, ages at puberty and outcome assessment, mean AAM, number
of cases, definition of outcome, types of outcomes (prevalent or incident T2D/IGT cases), risk
estimates with corresponding confidence intervals (CIs), definition of early puberty and its ref-
erence category, and variables controlled for in multivariable models. Specifically, for meta-
analysis, we selected (i) risk estimates for T2D/IGT per year later AAM as a continuous variable
(i.e., dose–response relationship) and (ii) risk estimates for T2D/IGT in the earlier AAM cate-
gory compared to the middle or older AAM category (i.e., categorical relationship). We distin-
guished between estimates from models adjusted for potential confounders (but not adiposity)
and estimates from models adjusted for an adiposity indicator (usually BMI or waist circumfer-
ence; if available, estimates adjusted for both were preferentially extracted). If a study reported
estimates for multiple outcomes, we prioritised the risk estimate for combined T2D/IGT, fol-
lowed by T2D only and IGT only, and included the estimate for only 1 such outcome per study.
For those studies that reported risk estimates for T2D/IGT per year earlier (rather than
later) AAM [17], we calculated the reciprocals to produce risk estimates per year later AAM.
Similarly, for those studies that reported risk estimates for T2D/IGT in an older (rather than
earlier) AAM category [12,18–21] compared to an earlier AAM category as the reference, we
calculated the reciprocals to produce risk estimates in the earlier AAM category compared to
the older AAM category as the reference. We considered odds ratios (ORs) and hazard ratios
(HRs) to be similar estimates of the relative risk (RR) since findings were similar by these mea-
sures of association.
Data synthesis and analysis
To summarise the association between AAM and T2D/IGT, we produced inverse-variance-
weighted random-effects models, which allow for heterogeneity among individual study effect
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estimates. Estimates from models with and without adjustment for adiposity indicators were
considered separately. Heterogeneity between studies was quantified by the inconsistency
index (I2) (<50%, 50%–75%, and>75% indicated mild, moderate, and high heterogeneity,
respectively). Potential sources of heterogeneity were evaluated using meta-regression analy-
ses. Asymmetry was evaluated using visual inspection of funnel plots and Egger’s regression
test. Sensitivity analyses by the trim-and-fill and leave-one-out methods were performed. Sta-
tistical analyses were performed using the “metafor” package in R software [22]. p-
Values < 0.05 were considered to indicate statistical significance.
Based on the causal assumption that AAM affects T2D/IGT risk, which underlies the inter-
pretation of population attributable risk as the proportion of preventable disease [23], the pop-
ulation attributable risk for T2D/IGT due to early menarche among British women was
calculated using the formula
pðRR  1Þ
pðRR  1Þþ1, where p is the prevalence of early menarche (defined as
<12 years) in the large population-based UK Biobank study [24], and RR is the pooled risk
estimate among white populations.
Quality assessment
The Newcastle–Ottawa Quality Assessment Scale for cohort studies [25] was used to assess the
quality of each study included in the systematic review. Criteria for each item in the assessment
scale were defined according to the present research topic before study quality assessments
were performed. For longitudinal studies of incident T2D/IGT and longitudinal studies that
assessed puberty timing in adolescence and early adulthood and subsequent prevalent T2D/
IGT, all 8 items were applied (maximum score of 9). For cross-sectional studies of prevalent
T2D/IGT, only 6 items (maximum score of 7) were used (presence of T2D/IGT at baseline and
follow-up duration were not relevant).
Results
Study characteristics
Study selection is summarised in Fig 1. The search strategy identified 6,155 records. After
screening based on titles and abstracts, and removing duplicates and non-relevant studies, 49
texts were selected for full-text reading, and finally 28 studies were deemed eligible for inclu-
sion in the review. All 10 studies included in the previous review [11] and studies in the refer-
ence lists of included studies were found in the databases by our search strategy.
Tables 1 and 2 (and S2 and S3 Tables) show the characteristics of the included studies for
the outcomes prevalent and incident cases of T2D/IGT, respectively. Of the 28 included stud-
ies, all assessed AAM in women (combined N = 1,228,306), and only 1 additionally analysed
age at voice breaking in men [24]. Data on puberty timing was collected during middle to late
adulthood in most studies (mean age ranging from 35 to 70 years), except during adolescence
in 1 study [26] and in early adulthood (age < 25 years) in 2 studies [17,27]. All were observa-
tional studies, and 1 additionally included a Mendelian randomisation analysis [13]. Nine
studies were conducted among white individuals [18,19,24,26–31], 13 studies among Asian
individuals (Chinese, Bangladeshi, Korean, and Japanese) [12,13,20,21,32–40], and 6 studies
among multi-ethnic populations (white, Hispanic, Asian, African-American, and Latino)
[17,41–45]. Fourteen studies examined prevalent T2D [13,18,19,24,26,27,30,34,36–39,43,45], 2
prevalent IGT [21,32], 3 prevalent T2D and IGT [28,33,35], 8 incident T2D [12,17,20,29,
31,40,41,44], and 1 prevalent and incident T2D [42]. The definitions of T2D and IGT varied
across studies, and 4 studies excluded participants with potential type 1 diabetes based on age
at diagnosis [24,26,42,43]. Adiposity indicators were adjusted for in 25 studies and were mostly
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BMI alone (n = 19) [17–21,26–31,35,37,39–41,43–45], followed by both BMI and waist cir-
cumference (n = 4) [12,34,36,42], waist circumference alone (n = 1) [32], and body composi-
tion (n = 1) [24]. Early menarche was defined as AAM< 12 years in 9 studies [17,24,29–
31,38,41–43] and <14 years in 13 studies [12,18,20,21,32–37,39,40,44], while the reference cat-
egory of AAM was defined as AAM� 12 years in 12 studies [24,29–31,33,35–37,41–44] and
�14 years in 10 studies [12,17,18,20,21,32,34,38–40]. Furthermore, the reference category of
AAM was the middle category in 12 studies [24,29–31,34–36,39,41–44] and the oldest category
in 10 studies [12,17,18,20,21,32,33,37,38,40]. Most studies (n = 18) tested the association of
AAM with T2D/IGT risk using logistic regression models and reported ORs [13,18,19,21,24,
27,30,32–42], while 6 studies used Cox proportional-hazards models and reported HRs
[12,17,20,26,29,44], and 4 studies reported RRs using Poisson regression [28,43], log binomial
regression [45], or generalised linear modelling [31].
For models without adjustment for adiposity, most studies (n = 20/24) reported a statisti-
cally significant association with higher T2D/IGT risk for earlier menarche [12,13,17,19,20,
24,26,28–32,35–37,39,41–44] or earlier voice breaking [24]; only 3 reported no association
[34,38,40], and 1 study reported that earlier menarche was associated with lower T2D/IGT risk
[33]. For models with adjustment for adiposity, some studies (n = 11/24) reported a statistically
significant association with higher T2D/IGT risk for earlier menarche [12,24,28,30–32,35–
37,39,43] or earlier voice breaking [24], but other studies did not (n = 11) [17–21,26,27,34,
40,42,44], and 2 studies reported inconsistent findings between dose–response and categorical
AAM models [29] or between sub-cohorts [41].
Quality assessment
More than half of studies of prevalent T2D/IGT (n = 11 studies) scored 6/7, followed by 5/7
(n = 4), 7/7 (n = 3), and 5/9 (n = 2) (S4 Table). Longitudinal studies of incident T2D/IGT were
rated 9/9 (n = 5) or 8/9 (n = 4) (S5 Table).
Meta-analysis results
All 28 studies on AAM and T2D/IGT in women were included in the meta-analysis. Similar
findings were observed for pooled estimates for T2D only and IGT only (S1 and S2 Figs). To
Fig 1. Flowchart of study selection.
https://doi.org/10.1371/journal.pmed.1003017.g001
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Table 1. Summary of eligible studies of prevalent diabetes/IGT.
First
author, year
[reference]
N total (N
cases)
Study; ethnicity Year at
enrolment
AAM (y)a Age at
outcome
assessment
(y)a
Outcome:
Definition
Measure of
association
Adiposity-
unadjusted RR
(95% CI)
Adiposity-
adjusted RR
(95% CI)
Adiposity
covariate
Cooper,
2000 [27]
668 (49) Menstruation
and
Reproductive
History; white
1934–1939 12.4
(range:
8–18)
73 (range:
63–81)
Diabetes:
Self-reported
physician
diagnosis
OR — 1.1 (0.9, 1.3)
per year
BMI
Saquib, 2005
[18]
997 (125) Rancho
Bernardo; white
1984–1987 <12:
14.5%; 12–
15: 78.9%;
�16: 6.6%
69.5 ± 9.3
(range: 50–
92)
Diabetes:
OGTT,
physician
diagnosis, or
anti-diabetic
medication
OR — 2.27 (0.62,
9.09)b, p =
0.21, <12 vs.
�16 (Ref)
BMI
Heys, 2007
[32]
7,108 (—) Guangzhou
Biobank;
Chinese
2003–2004 15.4 ± 2.1
(range:
8–25)
64.0 ± 6.0
(range: 50–
94)
IGT: Fasting
glucose or
anti-diabetic
medication
OR 1.40 (1.15, 1.71),
<12.5 vs. �14.5
(Ref)
1.33 (1.08,
1.63), <12.5
vs. �14.5
(Ref)
WC
Lakshman,
2008 [19]
13,308 (734) EPIC-Norfolk;
mainly white
1993–1997 13.0 ± 1.6 40–75 Diabetes:
Self-reported
physician
diagnosis or
anti-diabetic
medication
OR 0.91 (0.87, 0.96)
per year, p<
0.001; 1.52
(1.18, 1.96)b, p-
trend = 0.001,
8–11 vs. 15–18
(Ref)
0.98 (0.93,
1.03) per
year, p = 0.4
BMI
Akter, 2012
[33]
1,423 (—) Gabindagonj
Upazilla;
Bangladeshi
2009–2010 Unknown 40.9 to 42.7
(by AAM
group)
Diabetes:
Physician
diagnosis or
anti-diabetic
medication
IGT: fasting
glucose
OR 0.65 (0.46, 0.93),
p-trend = 0.02,
<12 vs. >13–16
(Ref)
— —
Dreyfus,
2012 [42]
8,491 (990) ARIC; white,
African-
American
1987–1989 12.9 ± 1.6 50.6 ± 9.3 Diabetes:
Fasting/non-
fasting
glucose, self-
reported
physician-
diagnosis, or
anti-diabetic
medication
OR 1.37 (1.12, 1.68),
p< 0.05, 8–11
vs. 13 (Ref)
1.20 (0.97,
1.48),
p> 0.05,
8–11 vs. 13
(Ref)
BMI, WC
Pierce, 2012
[26]
1,632 (26) NSHD; white 1946 13.2
(range:
8.5–19.5)
31, 36, 43, 53 Diabetes:
Ever treated
HR 0.72 (0.52, 0.99)
per year, p =
0.05
0.86 (0.63,
1.18) per
year, p = 0.5
BMI
Stockl, 2012
[28]
1,503 (366) KORA; white 2006–2008 13.5 ± 1.6 Range: 25–
74
Diabetes:
OGTT,
physician
diagnosis, or
anti-diabetic
medication
IGT: OGTT
RR 0.88 (0.83, 0.94)
per year, p<
0.001
0.89 (0.83,
0.95) per
year , p<
0.001
BMI
Qiu, 2013
[34]
3,304 (738) Chinese 2011–2012 Median:
16 (IQR:
15–18)
59 (range:
37–92)
Diabetes:
OGTT,
physician
diagnosis, or
anti-diabetic
medication
OR 0.94 (0.70, 1.26),
p = 0.682, 9–14
vs. 16 (Ref)
0.90 (0.66,
1.21), p =
0.479, 9–14
vs. 16 (Ref)
BMI, WC
(Continued)
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Table 1. (Continued)
First
author, year
[reference]
N total (N
cases)
Study; ethnicity Year at
enrolment
AAM (y)a Age at
outcome
assessment
(y)a
Outcome:
Definition
Measure of
association
Adiposity-
unadjusted RR
(95% CI)
Adiposity-
adjusted RR
(95% CI)
Adiposity
covariate
Mueller,
2014 [43]
8,075 (1,335) ELSA-Brasil;
white and black
Brazilian
2008–2010 12.7 ± 1.7 52.0 ± 8.8
(range: 35–
74)
Diabetes:
OGTT,
HbA1c,
physician
diagnosis, or
anti-diabetic
medication
RR 1.34 (1.14, 1.57),
<11 vs. 13–14
(Ref)
1.26 (1.07,
1.49), <11
vs. 13–14
(Ref)
BMI
Baek, 2015
[35]
2,039 (905) Sungkyunkwan
University;
Korean
2012–2013 14.6 ± 1.6 48.9 ± 3.5
(range: 44–
56)
Diabetes:
OGTT,
HbA1c,
physician
diagnosis, or
anti-diabetic
medication
IGT: fasting
glucose or
HbA1c
OR 1.85 (1.28, 2.66),
p = 0.001, <13
vs. 13–16 (Ref)
1.66 (1.14,
2.41), p =
0.008, <13
vs. 13–16
(Ref)
BMI
Day, 2015
[24]
250,037 (4,836) UK Biobank;
white
2006–2010 13.0 ± 1.6
(range:
8–19)
56.52 ± 8.09
(range: 40–
69)
Diabetes:
Self-reported
physician
diagnosis
OR 0.87 (0.85, 0.88)
per year, p<
0.001; 1.76
(1.62, 1.91), p<
0.001, 8–11 vs.
13–14 (Ref)
0.94 (0.92,
0.96) per
year, p<
0.001; 1.25
(1.15, 1.36),
p< 0.001,
8–11 vs. 13–
14 (Ref)
Body
comp.
Hwang, 2015
[36]
3,254 (—) KNHANES IV;
Korean
2007–2009 15.67 64.1 (range:
50–85)
Diabetes:
Self-reported
physician
diagnosis
(including
type 1 and 2)
OR 1.86 (1.07, 3.23),
p< 0.05, 10–12
vs. 13–15 (Ref)
1.82 (1.03,
3.23), p<
0.05, 10–12
vs. 13–15
(Ref)
BMI, WC
Lim, 2015
[37]
4,326 (119) KNHANES IV;
Korean
2007–2009 13.0 to
14.3 (by
age group)
Range: 20–
50
Diabetes:
Fasting
glucose, self-
reported
physician
diagnosis, or
anti-diabetic
medication
OR 3.61 (1.90, 6.88),
p< 0.05, <12
vs.�12 (Ref)
2.52 (1.29,
4.94), p<
0.05, <12 vs.
�12 (Ref)
BMI
Cao, 2016
[21]
1,625 (—) Changsha
Women’s Health
Screening
Program;
Chinese
2011–2014 — 60.45 ± 8.19
(range: 40–
75)
IGT: Fasting
glucose
OR — 0.83 (0.62,
1.10)b, 11–
13 vs. 16–20
(Ref)
BMI
Won, 2016
[38]
12,336 (—) KNHANES;
Korean
2010–2013 14.6 45.7 Diabetes:
Self-reported
physician
diagnosis
OR 1.72 (0.94, 3.15),
p = 0.077, <11
vs.�17 (Ref)
— —
Yang, 2016
[39]
16,114 (832) Jinchang
Cohort; Chinese
2011–2013 14.8 ± 2.0 45.8 ± 11.8 Diabetes:
Fasting
glucose or
anti-diabetic
medication
OR 1.60 (1.16, 2.22),
p< 0.05,�12
vs. 15–16 (Ref)
1.44 (1.02,
2.03), p<
0.05,�12 vs.
15–16 (Ref)
BMI
Au Yeung,
2017 [13]
12,484 (—) Guangzhou
Biobank;
Chinese
2003–2008 14.3 to
15.9 (by
age group)
�50 Diabetes:
Fasting
glucose or
anti-diabetic
medication
OR 0.92 (0.89, 0.95)
per year
— —
(Continued)
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maximise power, we therefore prioritised risk estimates for combined T2D/IGT (3 studies),
followed by T2D only (23 studies) and IGT only (2 studies).
Fig 2 shows the association between continuous AAM and T2D/IGT. From models without
adjustment for adult adiposity, pooled analysis of 11 estimates from 10 studies showed that
later AAM was associated with lower T2D/IGT risk (RR = 0.91 per year, 95% CI 0.89–0.93, p
< 0.001, n = 833,529; Fig 2A). This association was weaker but still evident in models with
adjustment for adiposity (pooled analysis of 12 estimates from 11 studies: RR = 0.97 per year,
95% CI 0.95–0.98, p< 0.001, n = 852,268; Fig 2B). Similar findings were obtained in subgroup
analyses by prevalent or incident T2D/IGT (Fig 2). Heterogeneity between studies was high in
estimates without adjustment for adiposity (I2 = 85.4%) and moderate in estimates with adjust-
ment for adiposity (I2 = 51.8%).
Fig 3 shows the association between categorical early versus later menarche and T2D/IGT.
From models without adjustment for adult adiposity, pooled analysis of 23 estimates from 21
studies showed that early menarche was associated with higher T2D/IGT risk (RR = 1.39, 95%
CI 1.25–1.55, p< 0.001, n = 1,185,444; Fig 3A). This association was weaker but still evident in
models with adjustment for adiposity (pooled analysis of 21 estimates from 19 studies:
RR = 1.19, 95% CI 1.11–1.28, p< 0.001, n = 890,583; Fig 3B). Similar findings were obtained
in subgroup analyses by prevalent or incident T2D/IGT (Fig 3). Heterogeneity between studies
was high in estimates without adjustment for adiposity (I2 = 87.8%) and moderate in estimates
with adjustment for adiposity (I2 = 68.1%).
Meta-regression results
Table 3 shows results of univariable meta-regression and pooled RRs by subgroups of studies.
Heterogeneity between studies was partially explained by study-level differences in ethnicity
and average AAM. The T2D/IGT risk associated with earlier menarche (both continuous and
categorical) was even higher among studies of white individuals than that among Asian indi-
viduals, and was also higher among populations with younger than older average AAM. Year
of enrolment, age at outcome assessment, number of variables adjusted for, age cutoff used to
define early menarche and the reference category, and measure of association (OR, HR, or
RR) did not explain the heterogeneity between study estimates (S6 Table).
Table 1. (Continued)
First
author, year
[reference]
N total (N
cases)
Study; ethnicity Year at
enrolment
AAM (y)a Age at
outcome
assessment
(y)a
Outcome:
Definition
Measure of
association
Adiposity-
unadjusted RR
(95% CI)
Adiposity-
adjusted RR
(95% CI)
Adiposity
covariate
Farahmand,
2017 [30]
4,952 (187) Tehran Lipid
and Glucose;
white
1998 13.3 ± 1.5 28.1 to 36.9
(by AAM
group)
Diabetes:
OGTT
OR 2.70 (1.40, 5.20),
<11 vs. 13–14
(Ref)
3.28 (1.50,
7.10), <11
vs. 13–14
(Ref)
BMI
Petersohn,
2019 [45]
30,626 (2,328) Mexican
National Health
survey; Mexican
1999–2000 13 37 to 45 (by
AAM group)
Diabetes:
Self-reported
physician
diagnosis or
OGTT
RR — 0.95 (0.83,
0.98) per
year, p<
0.001
BMI
aMean or mean ± SD unless otherwise indicated.
bResult was computed as the reciprocal of the risk estimate for the highest category.
AAM, age at menarche; BMI, body mass index; comp., composition; HR, hazard ratio; IGT, impaired glucose tolerance; OGTT, oral glucose tolerance test; OR, odds
ratio; RR, relative risk; WC, waist circumference; y, years.
https://doi.org/10.1371/journal.pmed.1003017.t001
Meta-analysis of puberty timing and diabetes
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003017 January 6, 2020 9 / 20
Table 2. Summary of eligible studies of incident diabetes/IGT.
First
author,
year
[reference]
Total N (N
cases)
Study; ethnicity Year at
enrolment
AAM (y)a Age at
outcome
assessment
or duration
of follow-up
(y)a
Outcome:
Definition
Measure of
association
Adiposity-
unadjusted RR
(95% CI)
Adiposity-
adjusted RR
(95% CI)
Adiposity
covariate
He, 2010
[41]
101,415 (7,963) Nurses’ Health;
multi-ethnic
1980 — 63.5 Diabetes:
OGTT,�1
diabetes
symptom or
anti-diabetic
medication
OR 0.94 (0.92, 0.95)
per year,
p< 0.05; 1.21
(1.13, 1.31),
p< 0.001,�11
vs. 13 (Ref)
0.99 (0.97,
1.01) per year,
p > 0.05; 1.02
(0.95, 1.10), p
= 0.42,�11
vs. 13 (Ref)
BMI
100,547 (2,739) Nurses’ Health
II; multi-ethnic
1991 — 47.4 0.88 (0.86, 0.91)
per year, p<
0.05; 1.50 (1.34,
1.69), p<
0.001,�11 vs.
13 (Ref)
0.97 (0.94,
1.00) per year,
p > 0.05; 1.15
(1.02, 1.29), p
= 0.19,�11
vs. 13 (Ref)
BMI
Conway,
2012 [20]
69,385 (1,831) Shanghai
Women’s
Health; Chinese
1997–2000 — 60.1 ± 2.0 Diabetes:
OGTT or
anti-diabetic
medication
HR 0.95 (0.92, 0.98)
per year; 1.35
(1.14, 1.59)b,
8–13 vs. 17–26
(Ref)
0.98 (0.95,
1.01) per year;
1.14 (0.95,
1.33)b, 8–13
vs. 17–26
(Ref)
BMI
Dreyfus,
2012 [42]
7,501 (755) ARIC; white,
African-
American
1987–1989 12.9 ± 1.6 56.8 ± 8.0 Diabetes:
fasting/non-
fasting
glucose, self-
reported
physician-
diagnosis, or
anti-diabetic
medication
OR 1.27 (1.02,
1.58), p< 0.05,
8–11 vs. 13
(Ref)
1.18 (0.95,
1.47),
p > 0.05,
8–11 vs. 13
(Ref)
—
Elks, 2013
[29]
10,903 (4,242) EPIC-InterAct;
white
1991 13.14 ± 1.58 52 Diabetes:
Health-
record-
confirmed
self-
reported
physician
diagnosis
HR 0.89 (0.86, 0.93)
per year, p<
0.001; 1.70
(1.48, 1.94), p<
0.001, 8–11 vs.
13 (Ref)
0.96 (0.91,
1.01) per year,
p = 0.11; 1.42
(1.18, 1.71), p
< 0.001, 8–11
vs. 13 (Ref)
BMI
Dreyfus,
2015 [17]
1,970 (271) CARDIA; white,
African-
American
1985 12.6 ± 1.5
(range:
8–16)
50 (range:
42–59)
Diabetes:
OGTT or
anti-diabetic
medication
HR 0.93 (0.86, 1.00)
per yearc, 1.61
(1.09, 2.37),
8–11 vs. 14–17
(Ref)
0.90 (0.86,
0.94) per
yearc, 1.33
(0.90, 1.96),
8–11 vs. 14–
17 (Ref)
BMI
LeBlanc,
2017 [44]
124,379 (11,262) Women’s
Health
Initiative; multi-
ethnic
1993–1998 — Follow-up:
12.2 ± 4.2
Diabetes:
Self-
reported
diagnosis or
anti-diabetic
medication
HR 1.14 (1.08,
1.20), p<
0.001, <12 vs.
12 (Ref)
1.01 (0.95,
1.06), p =
0.89, <12 vs.
12 (Ref)
BMI
Yang, 2018
[12]
270,345 (5,391) China Kadoorie
Biobank;
Chinese
2004–2008 15.4 ± 1.9 Follow-up: 7 Diabetes:
Health
records
HR 0.96 (0.94, 0.97)
per year, p-
trend < 0.001;
1.33 (1.24,
1.44)b, 13 vs.
�18 (Ref)
0.98 (0.97,
1.00) per year
BMI, WC
(Continued)
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Sensitivity analyses
S3 Fig shows some asymmetry in funnel plots for studies on the association between categori-
cal early menarche and T2D/IGT, which was statistically significant only for the studies on
early versus later menarche and T2D/IGT with adjustment for adiposity (Egger’s test, p<
0.001). The predominant source of asymmetry was the small studies, whereas the findings of
the larger studies appeared to be consistent with the overall estimates.
Sensitivity analyses were performed to account for this asymmetry. S4 Fig shows the pre-
dicted missing studies using the trim-and-fill method. When the predicted missing studies
were added to the meta-analyses, the associations between earlier continuous AAM (adipos-
ity-unadjusted RR = 0.91 per year, 95% CI 0.89–0.94; adiposity-adjusted RR = 0.97 per year,
95% CI 0.95–0.98) and categorical AAM (adiposity-unadjusted RR = 1.35, 95% CI 1.21–1.49;
adiposity-adjusted RR = 1.15, 95% CI 1.06–1.24) and higher T2D/IGT risk remained similar.
S5 Fig shows the results of leave-one-out analyses. When 1 of the study estimates was itera-
tively removed from the meta-analysis, the pooled estimates remained nearly unchanged for
associations between earlier AAM (continuous and categorical) and higher T2D/IGT risk,
with or without adjustment for adiposity.
Contribution of early menarche to the burden T2D
In light of the observed higher T2D/IGT risk associated with early menarche in white than
Asian individuals, and the availability of data from UK Biobank—a very large population-
based study of predominantly white adults—we used the pooled RR in white populations and
the prevalence of early menarche in white women in UK Biobank to estimate the current max-
imum contribution of early menarche to the burden of T2D. The estimated population
Table 2. (Continued)
First
author,
year
[reference]
Total N (N
cases)
Study; ethnicity Year at
enrolment
AAM (y)a Age at
outcome
assessment
or duration
of follow-up
(y)a
Outcome:
Definition
Measure of
association
Adiposity-
unadjusted RR
(95% CI)
Adiposity-
adjusted RR
(95% CI)
Adiposity
covariate
Pandeya,
2018 [31]
126,721 (4,073) InterLACE;
mainly white
1985–2009 13.1 (range:
8–20)
56.1 ± 11.4 Diabetes:
Self-
reported
physician
diagnosis or
health
records
RR 1.63 (1.40,
1.89),�10 vs.
13 (Ref)
1.18 (1.02,
1.37),�10 vs.
13 (Ref)
BMI
Nanri,
2019 [40]
37,511 (513) Japan Public
Health Center-
based
Prospective
Study; Japanese
1990, 1993 14.7 ± 1.9 Follow-up:
10
Diabetes:
Health-
record-
confirmed
self-
reported
physician
diagnosis
OR 1.09 (0.83,
1.43)b, p-
trend = 0.44,
�13 vs.�16
(Ref)
1.01 (0.76,
1.33)b, p-
trend = 0.82,
�13 vs. �16
(Ref)
BMI
aMean or mean ± SD unless otherwise indicated.
bResult was computed as the reciprocal of the risk estimate for the highest category.
cResult was computed as the reciprocal of the risk estimate per year earlier AAM.
AAM, age at menarche; BMI, body mass index; HR, hazards ratio; IGT, impaired glucose tolerance; OGTT, oral glucose tolerance test; OR, odds ratio; RR, relative risk;
WC, waist circumference; y, years.
https://doi.org/10.1371/journal.pmed.1003017.t002
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Fig 2. Forest plots of the association between AAM (continuous variable) and T2D/IGT, without and with adjustment for adiposity. (A) Without
and (B) with adjustment for adiposity. Two cohort studies in He, 2010 [41]. AAM, age at menarche; IGT, impaired glucose tolerance; RR, relative risk;
T2D, type 2 diabetes.
https://doi.org/10.1371/journal.pmed.1003017.g002
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attributable risk for T2D/IGT due to early menarche (<12 years) among white British women
(prevalence 20.15% in UK Biobank) unadjusted for adult adiposity was 12.6% (95% CI 11.0%–
14.3%, p< 0.001) and adjusted for adult adiposity was 5.1% (95% CI 3.6%–6.7%, p< 0.001).
Discussion
The present meta-analysis of observational studies showed that earlier AAM is associated with
higher T2D/IGT risk; this association is weaker but still evident after adjustment for adult adi-
posity. Study quality was in general high, and, despite evidence of asymmetry due to small
study effects in 1 of the 4 models, similar findings were obtained in sensitivity analyses that
considered predicted missing studies. Heterogeneity between studies was high and was par-
tially explained by study differences in ethnicity and average AAM, with stronger associations
in white women and in study populations with lower average AAM. Assuming a causal rela-
tionship [23], a significant proportion of T2D/IGT among white British women may be attrib-
utable to early menarche (before age 12 years). We found a paucity of studies on puberty
timing and T2D/IGT in men.
Our meta-analysis findings are consistent with a previous review [11], which reported asso-
ciations of younger AAM and early menarche with higher T2D risk with adjustment for adi-
posity, but we (i) included a larger number of studies (19 versus 10) and women (890,583
versus 315,428), (ii) distinguished between findings unadjusted and adjusted for adiposity, and
(iii) identified reasons for heterogeneity. While the previous meta-analysis [11] found an asso-
ciation of early menarche with higher T2D risk in Europe and the United States, we included
more Asian studies and demonstrated that this association was also apparent in Asian individ-
uals, although weaker than in white individuals, possibly due to their later average AAM. One
Fig 3. Forest plots of the association between early versus later menarche and T2D/IGT, without and with
adjustment for adiposity. (A) Without and (B) with adjustment for adiposity. Two cohort studies in He, 2010 [41].
AAM, age at menarche; IGT, impaired glucose tolerance; RR, relative risk; T2D, type 2 diabetes.
https://doi.org/10.1371/journal.pmed.1003017.g003
Table 3. Univariable meta-regression results (R2 and p-values) and pooled RR for diabetes and impaired glucose tolerance in study subgroups.
Factor and
subgroup
RR per year later age at menarche Early versus later (Ref) menarche
Not adiposity adjusted Adiposity adjusted Not adiposity adjusted Adiposity adjusted
N RR (95% CI) p-
Valuea
R2
(%)
N RR (95% CI) p-
Valuea
R2
(%)
N RR (95% CI) p-
Valuea
R2
(%)
N RR (95% CI) p-
Valuea
R2
(%)
Ethnicity 53.7 99.63 37.9 16.3
Asian 3 0.95 (0.92, 0.97) 2 0.98 (0.97, 0.99) 11 1.33 (1.06, 1.69) 9 1.23 (1.02, 1.49)
White 5 0.88 (0.86, 0.90) 0.002 6 0.95 (0.92, 0.98) 0.001 5 1.72 (1.61, 1.83) 0.013 5 1.27 (1.18, 1.36) 0.290
Multi-ethnic 3 0.91 (0.87, 0.96) 0.154 4 0.98 (0.96, 1.00) 0.871 7 1.30 (1.18, 1.42) 0.743 7 1.11 (1.02, 1.20) 0.472
Study average
AAM, yearsb
33.3 0 38 18.9
<13.5 5 0.89 (0.86, 0.91) 6 0.96 (0.93, 0.98) 8 1.59 (1.45, 1.75) 7 1.26 (1.19, 1.34)
�13.5 2 0.92 (0.85, 1.01) 0.154 2 0.94 (0.86, 1.03) 0.719 8 1.36 (1.17, 1.58) 0.036 6 1.27 (1.03, 1.55) 0.820
p-Value for
linear trendc
<0.001 0.400 0.014 0.677
N is the number of estimates; R2 (%) is the percent of heterogeneity explained.
aThe reference category in meta-regression models is the first subgroup in each factor.
bStudies that did not report the information were excluded.
cUsing study average AAM as a continuous variable.
AAM, age at menarche; RR, relative risk.
https://doi.org/10.1371/journal.pmed.1003017.t003
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study in China reported higher HRs for incident diabetes associated with younger AAM in
women born in the 1960s–1970s than in the 1950s and 1920s–1940s, consistent with the
decreased mean AAM over time, from 16.2 years in the 1920s–1940s to 14.7 years in the
1960s–1970s [12]. Hence, in light of worldwide secular trends towards lower average AAM
[5,7–9], not only are more women moving into the high-risk group (early menarche), but also
the magnitude of elevated risk in this group appears to be increasing.
The mechanisms that underlie the association between earlier AAM and higher T2D/IGT
risk are unclear. Rapid postnatal weight gain [46] and childhood obesity [47,48] may precede
early menarche, but also early menarche may promote adulthood obesity [49], and conse-
quently increase T2D risk [3,50,51]. Hence, adiposity may be considered as both a partial con-
founder and partial mediator. However, our meta-analysis found that the association between
earlier menarche and higher T2D/IGT risk remained, though attenuated, after accounting for
the potential confounding and mediating effects of adiposity, suggesting that there may be other
adiposity-independent underlying mechanisms. It has also been hypothesized that early menar-
che is a function of sex hormone exposure, such as higher levels of estradiol [52,53] and lower
sex-hormone-binding globulin concentrations [54], in women, which may affect glycaemic reg-
ulation and increase risk of diabetes [55–57]. Nonetheless, hormone replacement therapy, pre-
dominantly with estrogen, was shown to reduce the incidence of diabetes [58]. Estrogen may
have various effects on different parts of the body including brain, adipose tissue, breast, endo-
metrium, and endothelium, probably mediated by different estrogen receptors [59].
We acknowledge several limitations of our study. We could not directly test or quantify the
attenuation in the association when adjusting for adiposity, because the studies that contrib-
uted adjusted and unadjusted estimates were largely but not completely overlapping. All esti-
mates were from observational studies, and thus residual confounding may exist. AAM was
self-reported and was mainly recalled during adulthood, which may affect its accuracy; how-
ever, moderate correlations between prospective and recalled AAM several decades later have
been reported [60,61]. Average AAM and cutoffs for early menarche and the reference cate-
gory also varied across studies, and these were considered as sources of heterogeneity between
study estimates. Some asymmetry was detected, especially for the adiposity-adjusted associa-
tion between categorical early menarche and T2D/IGT, possibly indicating a bias towards
reporting positive findings; however, this potential bias appeared to affect only small studies,
and our sensitivity analyses were reassuring. Selection bias may exist due to the inclusion of
only papers with full reports in English. We did not find any potentially relevant papers in
other languages during screening of titles and abstracts in English, and our systematic review
included many studies conducted in non-English-speaking populations; however, it is possible
that other non-English studies are identifiable only in other publication databases. The sub-
group analyses by study average AAM were limited to studies that reported this value.
Although we examined relationships between both continuous and categorical AAM and
T2D/IGT risk, we were unable to examine if there was any threshold of AAM that indicates
higher risk of T2D/IGT, as was indicated by 1 large study [29]. Finally, we found only 1 study
of puberty timing and T2D/IGT in men, likely because measures of puberty timing in men are
not included in most studies. The 1 identified study was very large (n = 197,714) and reported
a statistically robust association between relatively younger (versus about average) voice break-
ing and T2D in white men (adiposity-unadjusted RR = 1.44, 95% CI 1.30–1.59, p< 0.001; adi-
posity-adjusted RR = 1.24, 95% CI 1.11–1.37, p< 0.001) [24]. However, more such studies are
needed, especially in non-white men, to understand whether the association could vary by
population, as observed for women.
In conclusion, this systematic review and meta-analysis of observational studies showed
that earlier AAM is consistently associated with higher T2D/IGT risk, independent of
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adiposity. This association is stronger among white individuals and populations with younger
average AAM. We estimated that a substantial proportion of T2D cases in UK women was
related to early menarche, and we would expect this proportion to increase in light of global
secular trends towards earlier puberty timing. These findings warrant further studies to iden-
tify potential underlying mechanisms linking early menarche to future T2D/IGT risk.
Supporting information
S1 PRISMA Checklist.
(DOC)
S1 Fig. Forest plots of the association of AAM (as a continuous variable) with T2D or IGT,
by prevalent or incident T2D/IGT. (A) Without and (B) with adjustment for adiposity.
(TIF)
S2 Fig. Forest plots of the association of early versus later menarche with T2D or IGT, by
prevalent or incident T2D/IGT. (A) Without and (B) with adjustment for adiposity.
(TIF)
S3 Fig. Funnel plots and Egger’s tests for studies using AAM (continuous variable) and
early menarche, with and without adjustment for adiposity. (A) AAM (continuous variable)
and (B) early menarche.
(TIF)
S4 Fig. Funnel plots with missing studies, with and without adjustment for adiposity, iden-
tified by the trim-and-fill method. (A) AAM (continuous variable) and (B) early menarche.
Open circles indicate filled missing studies.
(TIF)
S5 Fig. Forest plots of leave-one-out analysis, where each estimate in studies using AAM
(continuous variable) and early menarche, with and without adjustment for adiposity, was
iteratively removed. (A) AAM (continuous variable) and (B) early menarche.
(TIF)
S1 Table. Search strategy in different databases.
(DOCX)
S2 Table. Summary of eligible studies for prevalent diabetes and/or IGT.
(DOCX)
S3 Table. Summary of eligible studies for incident diabetes and/or IGT.
(DOCX)
S4 Table. Quality of eligible studies for prevalent diabetes/IGT assessed by the Newcastle–
Ottawa Quality Assessment Scale for cohort studies.
(DOCX)
S5 Table. Quality of eligible studies for incident diabetes/IGT assessed by the Newcastle–
Ottawa Quality Assessment Scale for cohort studies.
(DOCX)
S6 Table. Univariable meta-regression results and pooled RR for diabetes and IGT in
study subgroups.
(DOCX)
Meta-analysis of puberty timing and diabetes
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003017 January 6, 2020 16 / 20
Acknowledgments
We thank Stephen Sharp, MRC Epidemiology Unit, University of Cambridge, for statistical advice
and Veronica Phillips, Cambridge University Medical Library, for advice on systematic reviews.
Author Contributions
Conceptualization: Tuck Seng Cheng, Felix R. Day, Ken K. Ong.
Data curation: Tuck Seng Cheng, Rajalakshmi Lakshman, Ken K. Ong.
Formal analysis: Tuck Seng Cheng.
Methodology: Tuck Seng Cheng, Ken K. Ong.
Supervision: Ken K. Ong.
Validation: Ken K. Ong.
Writing – original draft: Tuck Seng Cheng.
Writing – review & editing: Tuck Seng Cheng, Felix R. Day, Rajalakshmi Lakshman, Ken K.
Ong.
References
1. Marshall WA, Tanner JM. Variations in the pattern of pubertal changes in boys. Arch Dis Child. 1970;
45:13–23. https://doi.org/10.1136/adc.45.239.13 PMID: 5440182
2. Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. Arch Dis Child. 1969;
44:291–303. https://doi.org/10.1136/adc.44.235.291 PMID: 5785179
3. Ahmed ML, Ong KK, Dunger DB. Childhood obesity and the timing of puberty. Trends Endocrinol
Metab. 2009; 20:237–42. https://doi.org/10.1016/j.tem.2009.02.004 PMID: 19541497
4. Harries M, Walker JM, Williams DM, Hawkins S, Hughes I. Changes in the male voice at puberty. Arch
Dis Child. 1997; 77:445–7. https://doi.org/10.1136/adc.77.5.445 PMID: 9487971
5. Sorensen K, Mouritsen A, Aksglaede L, Hagen CP, Mogensen SS, Juul A. Recent secular trends in
pubertal timing: implications for evaluation and diagnosis of precocious puberty. Horm Res Paediatr
2012; 77:137–45. https://doi.org/10.1159/000336325 PMID: 22508036
6. Harrington J, Palmert MR. Clinical review: distinguishing constitutional delay of growth and puberty
from isolated hypogonadotropic hypogonadism: critical appraisal of available diagnostic tests. J Clin
Endocrinol Metab. 2012; 97:3056–67. https://doi.org/10.1210/jc.2012-1598 PMID: 22723321
7. Hosokawa M, Imazeki S, Mizunuma H, Kubota T, Hayashi K. Secular trends in age at menarche and
time to establish regular menstrual cycling in Japanese women born between 1930 and 1985. BMC
Womens Health. 2012; 12:19. https://doi.org/10.1186/1472-6874-12-19 PMID: 22800445
8. Cho GJ, Park HT, Shin JH, Hur JY, Kim YT, Kim SH, et al. Age at menarche in a Korean population:
secular trends and influencing factors. Eur J Pediatr. 2010; 169:89–94. https://doi.org/10.1007/s00431-
009-0993-1 PMID: 19504269
9. van der Eng P, Sohn K. The biological standard of living in Indonesia during the 20th century: evidence
from the age at menarche. Econ Hum Biol. 2019; 34:216–24. https://doi.org/10.1016/j.ehb.2018.11.004
PMID: 30551996
10. Kaiser AB, Zhang N, van der Pluijm W. Global prevalence of type 2 diabetes over the next ten years
(2018–2028). Diabetes. 2018; 67:202-LB.
11. Janghorbani M, Mansourian M, Hosseini E. Systematic review and meta-analysis of age at menarche
and risk of type 2 diabetes. Acta Diabetol. 2014; 51:519–28. https://doi.org/10.1007/s00592-014-0579-
x PMID: 24671509
12. Yang L, Li L, Peters SAE, Clarke R, Guo Y, Chen Y, et al. Age at menarche and incidence of diabetes: a
prospective study of 300,000 women in China. Am J Epidemiol. 2018; 187:190–8. https://doi.org/10.
1093/aje/kwx219 PMID: 28605451
13. Au Yeung SL, Jiang C, Cheng KK, Xu L, Zhang W, Lam TH, et al. Age at menarche and cardiovascular
risk factors using Mendelian randomization in the Guangzhou Biobank Cohort Study. Prev Med. 2017;
101:142–8. https://doi.org/10.1016/j.ypmed.2017.06.006 PMID: 28601624
Meta-analysis of puberty timing and diabetes
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003017 January 6, 2020 17 / 20
14. Evensen E, Wilsgaard T, Furberg AS, Skeie G. Tracking of overweight and obesity from early childhood
to adolescence in a population-based cohort—the Tromso Study, Fit Futures. BMC Pediatr. 2016;
16:64. https://doi.org/10.1186/s12887-016-0599-5 PMID: 27165270
15. Freedman DS, Khan LK, Serdula MK, Dietz WH, Srinivasan SR, Berenson GS. The relation of menar-
cheal age to obesity in childhood and adulthood: the Bogalusa heart study. BMC Pediatr. 2003; 3:3.
https://doi.org/10.1186/1471-2431-3-3 PMID: 12723990
16. Scottish Intercollegiate Guidelines Network. Search filters. Edinburgh: Scottish Intercollegiate Guide-
lines Network; 2019 [cited 2019 Feb 28]. Available from: https://www.sign.ac.uk/search-filters.html.
17. Dreyfus J, Jacobs DR Jr, Mueller N, Schreiner PJ, Moran A, Carnethon MR, et al. Age at menarche and
cardiometabolic risk in adulthood: the Coronary Artery Risk Development in Young Adults Study. J
Pediatr. 2015; 167:344–52.e1. https://doi.org/10.1016/j.jpeds.2015.04.032 PMID: 25962931
18. Saquib N, Kritz-Silverstein D, Barrett-Connor E. Age at menarche, abnormal glucose tolerance and
type 2 diabetes mellitus: the Rancho Bernardo Study. Climacteric. 2005; 8:76–82. https://doi.org/10.
1080/13697130500062688 PMID: 15804735
19. Lakshman R, Forouhi N, Luben R, Bingham S, Khaw K, Wareham N, et al. Association between age at
menarche and risk of diabetes in adults: results from the EPIC-Norfolk cohort study. Diabetologia.
2008; 51:781–6. https://doi.org/10.1007/s00125-008-0948-5 PMID: 18320165
20. Conway BN, Shu XO, Zhang X, Xiang YB, Cai H, Li H, et al. Age at menarche, the leg length to sitting
height ratio, and risk of diabetes in middle-aged and elderly Chinese men and women. PLoS ONE.
2012; 7(3):e30625. https://doi.org/10.1371/journal.pone.0030625 PMID: 22448212
21. Cao X, Zhou J, Yuan H, Chen Z. Duration of reproductive lifespan and age at menarche in relation to
metabolic syndrome in postmenopausal Chinese women. J Obstet Gynaecol Res. 2016; 42:1581–7.
https://doi.org/10.1111/jog.13093 PMID: 27718299
22. Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw. 2010; 36:1–48.
23. Levine B. What does the population attributable fraction mean? Prev Chronic Dis. 2007; 4:A14-A.
24. Day FR, Elks CE, Murray A, Ong KK, Perry JR. Puberty timing associated with diabetes, cardiovascular
disease and also diverse health outcomes in men and women: the UK Biobank study. Sci Rep. 2015;
5:11208. https://doi.org/10.1038/srep11208 PMID: 26084728
25. Stang A. Critical evaluation of the Newcastle–Ottawa scale for the assessment of the quality of nonran-
domized studies in meta-analyses. Eur J Epidemiol. 2010; 25:603–5. https://doi.org/10.1007/s10654-
010-9491-z PMID: 20652370
26. Pierce MB, Kuh D, Hardy R. The role of BMI across the life course in the relationship between age at
menarche and diabetes, in a British birth cohort. Diabet Med. 2012; 29:600–3. https://doi.org/10.1111/j.
1464-5491.2011.03489.x PMID: 21999522
27. Cooper GS, Ephross SA, Sandler DP. Menstrual patterns and risk of adult-onset diabetes mellitus. J
Clin Epidemiol. 2000; 53:1170–3. https://doi.org/10.1016/s0895-4356(00)00240-7 PMID: 11106892
28. Stockl D, Doring A, Peters A, Thorand B, Heier M, Huth C, et al. Age at menarche is associated with pre-
diabetes and diabetes in women (aged 32–81 years) from the general population: the KORA F4 Study.
Diabetologia. 2012; 55:681–8. https://doi.org/10.1007/s00125-011-2410-3 PMID: 22170465
29. Elks CE, Ong KK, Scott RA, van der Schouw YT, Brand JS, Wark PA, et al. Age at menarche and type
2 diabetes risk: the EPIC-InterAct study. Diabetes Care. 2013; 36:3526–34. https://doi.org/10.2337/
dc13-0446 PMID: 24159179
30. Farahmand M, Tehrani FR, Dovom MR, Azizi F. Menarcheal age and risk of type 2 diabetes: a commu-
nity-based cohort study. J Clin Res Pediatr Endocrinol. 2017; 9:156–62. https://doi.org/10.4274/jcrpe.
3370 PMID: 27840328
31. Pandeya N, Huxley RR, Chung HF, Dobson AJ, Kuh D, Hardy R, et al. Female reproductive history and
risk of type 2 diabetes: a prospective analysis of 126 721 women. Diabetes Obes Metab. 2018;
20:2103–12. https://doi.org/10.1111/dom.13336 PMID: 29696756
32. Heys M, Schooling CM, Jiang C, Cowling BJ, Lao X, Zhang W, et al. Age of menarche and the metabolic
syndrome in China. Epidemiology. 2007; 18:740–6. https://doi.org/10.1097/EDE.0b013e3181567faf
PMID: 17917601
33. Akter S, Jesmin S, Islam M, Sultana SN, Okazaki O, Hiroe M, et al. Association of age at menarche with
metabolic syndrome and its components in rural Bangladeshi women. Nutr Metab (Lond). 2012; 9:99.
34. Qiu C, Chen H, Wen J, Zhu P, Lin F, Huang B, et al. Associations between age at menarche and meno-
pause with cardiovascular disease, diabetes, and osteoporosis in Chinese women. J Clin Endocrinol
Metab. 2013; 98:1612–21. https://doi.org/10.1210/jc.2012-2919 PMID: 23471979
35. Baek TH, Lim NK, Kim MJ, Lee J, Ryu S, Chang Y, et al. Age at menarche and its association with dys-
glycemia in Korean middle-aged women. Menopause. 2015; 22:542–8. https://doi.org/10.1097/GME.
0000000000000353 PMID: 25335102
Meta-analysis of puberty timing and diabetes
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003017 January 6, 2020 18 / 20
36. Hwang E, Lee KW, Cho Y, Chung HK, Shin MJ. Association between age at menarche and diabetes in
Korean post-menopausal women: results from the Korea National Health and Nutrition Examination
Survey (2007–2009). Endocr J. 2015; 62:897–905. https://doi.org/10.1507/endocrj.EJ15-0192 PMID:
26194132
37. Lim JS, Lee HS, Kim EY, Yi KH, Hwang JS. Early menarche increases the risk of type 2 diabetes in
young and middle-aged Korean women. Diabet Med. 2015; 32:521–5. https://doi.org/10.1111/dme.
12653 PMID: 25441051
38. Won JC, Hong JW, Noh JH, Kim DJ. Association between age at menarche and risk factors for cardio-
vascular diseases in Korean women: the 2010 to 2013 Korea National Health and Nutrition Examination
Survey. Medicine. 2016; 95:e3580. https://doi.org/10.1097/MD.0000000000003580 PMID: 27149485
39. Yang A, Liu S, Cheng N, Pu H, Dai M, Ding J, et al. Reproductive factors and risk of type 2 diabetes in
an occupational cohort of Chinese women. J Diabetes Complications. 2016; 30:1217–22. https://doi.
org/10.1016/j.jdiacomp.2016.06.011 PMID: 27345735
40. Nanri A, Mizoue T, Noda M, Goto A, Sawada N, Tsugane S. Menstrual and reproductive factors and
type 2 diabetes risk: the Japan Public Health Center-based Prospective Study. J Diabetes Investig
2019; 10:147–53. https://doi.org/10.1111/jdi.12853 PMID: 29667360
41. He C, Zhang C, Hunter DJ, Hankinson SE, Buck Louis GM, Hediger ML, et al. Age at menarche and
risk of type 2 diabetes: results from 2 large prospective cohort studies. Am J Epidemiol. 2010; 171:334–
44. https://doi.org/10.1093/aje/kwp372 PMID: 20026580
42. Dreyfus JG, Lutsey PL, Huxley R, Pankow JS, Selvin E, Fernandez-Rhodes L, et al. Age at menarche
and risk of type 2 diabetes among African-American and white women in the Atherosclerosis Risk in
Communities (ARIC) study. Diabetologia. 2012; 55:2371–80. https://doi.org/10.1007/s00125-012-
2616-z PMID: 22760786
43. Mueller NT, Duncan BB, Barreto SM, Chor D, Bessel M, Aquino EM, et al. Earlier age at menarche is
associated with higher diabetes risk and cardiometabolic disease risk factors in Brazilian adults: Brazil-
ian Longitudinal Study of Adult Health (ELSA-Brasil). Cardiovasc Diabetol. 2014; 13:22. https://doi.org/
10.1186/1475-2840-13-22 PMID: 24438044
44. LeBlanc ES, Kapphahn K, Hedlin H, Desai M, Parikh NI, Liu S, et al. Reproductive history and risk of
type 2 diabetes mellitus in postmenopausal women: findings from the Women’s Health Initiative. Meno-
pause. 2017; 24:64–72. https://doi.org/10.1097/GME.0000000000000714 PMID: 27465714
45. Petersohn I, Zarate-Ortiz AG, Cepeda-Lopez AC, Melse-Boonstra A. Time trends in age at menarche
and related non-communicable disease risk during the 20th century in Mexico. Nutrients. 2019; 11:394.
46. Terry MB, Ferris JS, Tehranifar P, Wei Y, Flom JD. Birth weight, postnatal growth, and age at menar-
che. Am J Epidemiol 2009; 170:72–9. https://doi.org/10.1093/aje/kwp095 PMID: 19439580
47. Li W, Liu Q, Deng X, Chen Y, Liu S, Story M. Association between obesity and puberty timing: a system-
atic review and meta-analysis. Int J Environ Res Public Health 2017; 14:1266.
48. Mumby HS, Elks CE, Li S, Sharp SJ, Khaw KT, Luben RN, et al. Mendelian randomisation study of
childhood BMI and early menarche. J Obes. 2011; 2011:180729. https://doi.org/10.1155/2011/180729
PMID: 21773002
49. Trikudanathan S, Pedley A, Massaro JM, Hoffmann U, Seely EW, Murabito JM, et al. Association of
female reproductive factors with body composition: the Framingham Heart Study. J Clin Endocrinol
Metab. 2013; 98:236–44. https://doi.org/10.1210/jc.2012-1785 PMID: 23093491
50. Al-Goblan AS, Al-Alfi MA, Khan MZ. Mechanism linking diabetes mellitus and obesity. Diabetes Metab
Syndr Obes. 2014; 7:587–91. https://doi.org/10.2147/DMSO.S67400 PMID: 25506234
51. Eriksson JG, Forsen TJ, Osmond C, Barker DJP. Pathways of infant and childhood growth that lead to
type 2 diabetes. Diabetes Care. 2003; 26:3006–10. https://doi.org/10.2337/diacare.26.11.3006 PMID:
14578231
52. Vihko R, Apter D. Endocrine characteristics of adolescent menstrual cycles: impact of early menarche.
J Steroid Biochem. 1984; 20:231–6. https://doi.org/10.1016/0022-4731(84)90209-7 PMID: 6231419
53. Apter D, Vihko R. Early menarche, a risk factor for breast cancer, indicates early onset of ovulatory
cycles. J Clin Endocrinol Metab. 1983; 57:82–6. https://doi.org/10.1210/jcem-57-1-82 PMID: 6222061
54. Thankamony A, Ong KK, Ahmed ML, Ness AR, Holly JM, Dunger DB. Higher levels of IGF-I and adre-
nal androgens at age 8 years are associated with earlier age at menarche in girls. J Clin Endocrinol
Metab 2012; 97:E786–90. https://doi.org/10.1210/jc.2011-3261 PMID: 22419724
55. Ding EL, Song Y, Malik VS, Liu S. Sex differences of endogenous sex hormones and risk of type 2 dia-
betes: a systematic review and meta-analysis. JAMA. 2006; 295:1288–99. https://doi.org/10.1001/
jama.295.11.1288 PMID: 16537739
Meta-analysis of puberty timing and diabetes
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003017 January 6, 2020 19 / 20
56. O’Reilly MW, Glisic M, Kumarendran B, Subramanian A, Manolopoulos KN, Tahrani AA, et al. Serum
testosterone, sex hormone-binding globulin and sex-specific risk of incident type 2 diabetes in a retro-
spective primary care cohort. Clin Endocrinol (Oxf). 2019; 90:145–54.
57. Perry JR, Weedon MN, Langenberg C, Jackson AU, Lyssenko V, Sparso T, et al. Genetic evidence that
raised sex hormone binding globulin (SHBG) levels reduce the risk of type 2 diabetes. Hum Mol Genet.
2010; 19:535–44. https://doi.org/10.1093/hmg/ddp522 PMID: 19933169
58. Salpeter SR, Walsh JM, Ormiston TM, Greyber E, Buckley NS, Salpeter EE. Meta-analysis: effect of
hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women.
Diabetes Obes Metab. 2006; 8:538–54. https://doi.org/10.1111/j.1463-1326.2005.00545.x PMID:
16918589
59. Clegg D, Hevener AL, Moreau KL, Morselli E, Criollo A, Van Pelt RE, et al. Sex hormones and cardio-
metabolic health: role of estrogen and estrogen receptors. Endocrinology. 2017; 158:1095–105. https://
doi.org/10.1210/en.2016-1677 PMID: 28323912
60. Must A, Phillips SM, Naumova EN, Blum M, Harris S, Dawson-Hughes B, et al. Recall of early menstrual
history and menarcheal body size: after 30 years, how well do women remember? Am J Epidemiol.
2002; 155:672–9. https://doi.org/10.1093/aje/155.7.672 PMID: 11914195
61. Cooper R, Blell M, Hardy R, Black S, Pollard TM, Wadsworth ME, et al. Validity of age at menarche self-
reported in adulthood. J Epidemiol Community Health 2006; 60:993–7. https://doi.org/10.1136/jech.
2005.043182 PMID: 17053289
Meta-analysis of puberty timing and diabetes
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003017 January 6, 2020 20 / 20
